# MEDICAL FEE DISPUTE RESOLUTION FINDINGS AND DECISION 

## GENERAL INFORMATION

## Requestor Name

Memorial Compounding Pharmacy

## MFDR Tracking Number

M4-18-4097-01

Respondent Name
Ace American Insurance Co
Carrier's Austin Representative
Box Number 15

## MFDR Date Received

June 25, 2018

## REQUESTOR'S POSITION SUMMARY

Requestor's Position Summary: "The carrier denied the reconsideration based on lack of preauthorization. ...These medication due not require preauthorization therefore do not need preauthorization."

Amount in Dispute: \$566.53

## RESPONDENT'S POSITION SUMMARY

Respondent's Position Summary: "Our supplemental response for the above referenced medical fee dispute resolution is as follows: Based on Peer review and PLN11."

Response Submitted by: Gallagher Bassett

SUMMARY OF FINDINGS

| Dates of Service | Disputed Services | Amount In <br> Dispute | Amount Due |
| :---: | :---: | :---: | :---: |
| October 23,2017 | Compound Medication | $\$ 566.53$ | $\$ 566.53$ |

## FINDINGS AND DECISION

This medical fee dispute is decided pursuant to Texas Labor Code $\S 413.031$ and applicable rules of the Texas Department of Insurance, Division of Workers' Compensation.

## Background

1. 28 Texas Administrative Code $\S 133.307$ sets out the procedures for resolving medical fee disputes.
2. 28 Texas Administrative Code $\S 134.502$ sets out the procedures for pharmaceutical benefits.
3. 28 Texas Administrative Code $\S 134.503$ sets out the fee guidelines for pharmaceutical services.
4. 28 Texas Administrative Code $\S 134.530$ sets out the closed formulary requirements for claims not subject to certified networks.
5. The insurance carrier reduced payment for the disputed services with the following claim adjustment codes:

- 197 - Precertification/authorization/notification absent

1. Did the carrier raise a new defense pursuant to 28 Texas Administrative Code §133.307?
2. Is the carrier's reason for denial of payment supported?
3. Is the requestor entitled to reimbursement for the compound in question?

## Findings

1. In its position statement the requestor states, "...based on peer review and PLN11."

28 Texas Administrative Code §133.307(d)(2)(F) states, in relevant part, "The response shall address only those denial reasons presented to the requestor prior to the date the request for MFDR was filed with the division and the other party. Any new denial reasons or defenses raised shall not be considered in the review."

Review of the submitted documentation finds that the carrier failed to present a medical necessity denial to the provider in accordance with 28 Texas Administrative Code $\$ 133.240$ prior to the date the request for medical fee dispute resolution (MFDR) was filed. The division concludes that this defense presented in the respondent's position statement shall not be considered for review because this assertion constitutes a new defense pursuant to 28 Texas Administrative Code §133.307(d)(2)(F).
2. The requestor is seeking reimbursement of $\$ 566.53$ for compounded medication dispensed on October 23, 2017. The carrier denied the disputed compound with claim adjustment reason code "197Precertification/authorization/notification absent."

28 Texas Administrative Code $\S 134.530(b)(2)$ states that preauthorization is only required for:

- drugs identified with a status of " N " in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;
- any compound that contains a drug identified with a status of " N " in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates; and
- any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

The division finds that the medication in question is not identified as a drug with a status of " N " in the current edition of the ODG, Appendix $A$. Therefore, the division concludes that the medication in question did not require preauthorization and the carrier's denial of payment for this reason is not supported. Therefore, the disputed medication will be reviewed for reimbursement.
3. 28 Texas Administrative Code $\S 134.503$ applies to the medication in dispute and states, in pertinent part:
(c) The insurance carrier shall reimburse the health care provider or pharmacy processing agent for prescription drugs the lesser of:
(1) the fee established by the following formulas based on the average wholesale price (AWP) as reported by a nationally recognized pharmaceutical price guide or other publication of pharmaceutical pricing data in effect on the day the prescription drug is dispensed:
(A) Generic drugs: ((AWP per unit) $\times$ (number of units) $\times 1.25$ ) $+\$ 4.00$ dispensing fee per prescription = reimbursement amount;
(B) Brand name drugs: ((AWP per unit) $\times$ (number of units) $\times 1.09$ ) $+\$ 4.00$ dispensing fee per prescription = reimbursement amount;
(C) When compounding, a single compounding fee of $\$ 15$ per prescription shall be added to the calculated total for either paragraph (1)(A) or (B) of this subsection; or
(2) notwithstanding $\S 133.20(\mathrm{e})(1)$ of this title (relating to Medical Bill Submission by Health Care Provider), the amount billed to the insurance carrier by the:
(A) health care provider; or
(B) pharmacy processing agent only if the health care provider has not previously billed the insurance carrier for the prescription drug and the pharmacy processing agent is billing on behalf of the health care provider.

| Ingredient | NDC | Price/ Unit | Total <br> Units | AWP Formula <br> $\S 134.503(c)(1)$ | Billed Amt <br> $\S 134.503$ <br> $(c)(2)$ | Lesser of <br> $(\mathrm{c})(1)$ and <br> $(\mathrm{c})(2)$ |
| :--- | :--- | :---: | :---: | :---: | :---: | :---: |
| Meloxicam | 38779274601 | $\$ 194.67$ | 0.18 | $\$ 43.80$ | $\$ 35.04$ | $\$ 35.04$ |
| Flurbiprofen | 38779036209 | $\$ 36.58$ | 4.8 | $\$ 219.48$ | $\$ 175.58$ | $\$ 175.58$ |
| Tramadol | 38779237409 | $\$ 36.30$ | 6 | $\$ 272.25$ | $\$ 217.80$ | $\$ 217.80$ |
| Cyclobenzaprine | 38779039509 | $\$ 46.332$ | 1.8 | $\$ 104.25$ | $\$ 83.39$ | $\$ 83.39$ |
| Bupivacaine | 38779052405 | $\$ 45.60$ | 1.2 | $\$ 68.40$ | $\$ 54.72$ | $\$ 54.72$ |
|  |  |  |  |  | Total | $\$ 566.53$ |

The total reimbursement is $\$ 566.53$. This amount is recommended.

## Conclusion

For the reasons stated above, the Division finds that the requestor has established that additional reimbursement is due. As a result, the amount ordered is $\$ 566.53$.

## ORDER

Based on the submitted information, pursuant to Texas Labor Code Section 413.031 and 413.019 (if applicable), the division has determined the requestor is entitled to additional reimbursement for the disputed services. The division hereby ORDERS the respondent to remit to the requestor $\$ 566.53$, plus applicable accrued interest per 28 Texas Administrative Code $\S 134.130$, due within 30 days of receipt of this order.

## Authorized Signature

## Signature

Medical Fee Dispute Resolution Officer
July 19, 2018
Date

## YOUR RIGHT TO APPEAL

Either party to this medical fee dispute has a right to seek review of this decision in accordance with Rule §133.307, effective May 31, 2012, 37 Texas Register 3833, applicable to disputes filed on or after June 1, 2012.
A party seeking review must submit a Request to Schedule a Benefit Review Conference to Appeal a Medical Fee Dispute Decision (form DWCO45M) in accordance with the instructions on the form. The request must be received by the division within twenty days of your receipt of this decision. The request may be faxed, mailed or personally delivered to the division using the contact information listed on the form or to the field office handling the claim. The party seeking review of the MFDR decision shall deliver a copy of the request to all other parties involved in the dispute at the same time the request is filed. Please include a copy of the Medical Fee Dispute Resolution Findings and Decision together with any other required information specified in 28 Texas Administrative Code §141.1(d).

Si prefiere hablar con una persona en español acerca de ésta correspondencia, favor de llamar a 512-804-4812.

